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Abstract
Purpose of Review To review the current status and indications of transcatheter edge-to-edge mitral valve repair.
Recent Findings Mitral regurgitation remains a common valvular disease and can be classified as degenerative (primary) or
functional (secondary). Randomized controlled trials have shown that transcatheter edge-to-edge mitral valve repair with
MitraClip is successful, safe, and effective in reducing mitral regurgitation. The US Food and Drug Administration approved
MitraClip in 2013 for treatment of patients with primary mitral regurgitation at prohibitive surgical risk and in 2019 for secondary
mitral regurgitation. Several MitraClip generations exist (NT/R, XT/R, NTW, and XTW) with unique features and considerations. Additional edge-to-edge repair, non-edge-to-edge repair, and transcatheter valve replacement systems are under investigation as stand-alone or adjunctive therapy for patients with mitral regurgitation.
Summary Mitral regurgitation remains a significant health burden and many patients are not suitable for surgical repair or
replacement. Transcatheter mitral valve therapies can be considered in selected patients and are safe and effective. More research
is needed to understand how to best select devices and patients and optimize outcomes.
Keywords Transcatheter edge-to-edge mitral valve repair . MitraClip . Indications . Mitral valve regurgitation

Introduction
Mitral regurgitation (MR) remains a common valvular heart
disease that affects approximately 4 million people in the
United States (US) alone and its burden is projected to increase in the coming years [1, 2]. Although milder forms of
mitral regurgitation can usually be treated medically, severe
mitral regurgitation eventually leads to left ventricular (LV)
dilation and heart failure [3]. MR can be classified into degenerative (primary) or functional (secondary) MR. ACC/AHA
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guidelines [4, 5] recommend surgery (repair when possible)
for primary severe MR with class I, IIa, and IIb recommendations depending on the clinical scenario. However, many patients are not good surgical candidates, and therefore, only
approximately 50% of patients with an indication actually
undergo surgery [6]. Moreover, surgical treatment for secondary MR is only given a class IIb indication for persistently
symptomatic patients with severe secondary MR, reflective
of the equivocal data supporting surgical treatment in this
population. In recent years, transcatheter edge-to-edge mitral
valve repair systems (among other technologies) have been
developed as alternatives to surgery for patients with mitral
regurgitation. The purpose of this manuscript is to review the
relevant literature, indications, available devices, and limitations of transcatheter edge-to-edge mitral valve repair.

Supporting Data
The EVEREST II trial [7] was a randomized controlled comparison of transcatheter mitral repair (with the MitraClip system, Abbott, Abbott Park, IL) and mitral valve surgery for
patients with moderate to severe or severe MR (73% had
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primary MR). It showed that transcatheter repair with
MitraClip was less effective at reducing mitral regurgitation
than surgical treatment but that the procedure was associated
with superior safety and similar improvements in clinical outcomes. Furthermore, 5-year follow-up data from EVEREST II
[8] showed that there was no difference in mortality between
the surgical and transcatheter arms and a similar reduction in
New York Heart Association (NYHA) heart failure classification. There was also no difference between surgery and
MitraClip in terms of reintervention for residual MR between
1 and 5 years. The REALISM registry [9], a continued access
registry of EVEREST II, noted a better freedom from surgery
in patients treated with MitraClip as operator experience increased. Importantly, post hoc analysis from EVEREST II
showed that MitraClip was non-inferior to surgery in subsets
of patients who were older (> 70 years of age) or who had
functional MR.
The EVEREST High Risk Registry [10, 11] was conducted
to assess the safety and effectiveness of MitraClip in high-risk
patients with 3–4+ mitral regurgitation. It enrolled 78 patients
(59% with functional MR and 41% with degenerative MR).
At 12 months, survival was 76%, 78% had an MR grade ≤ 2+,
and NYHA functional class improved from III/IV at baseline
in 89% to class I/II in 74%. At 5 years, MR reduction
remained durable with 70% of surviving patients experiencing
MR reduction to ≤ 2+, and the majority of surviving patients
(83%) experienced reduced symptoms (NYHA Class I/II).
The COAPT trial [12] was a randomized controlled comparison of transcatheter edge-to-edge mitral repair with
MitraClip versus optimal medical therapy alone for patients
with moderate to severe or severe secondary MR who
remained symptomatic after optimal medical therapy. It
showed that transcatheter mitral valve repair with MitraClip
resulted in a lower rate of hospitalization for heart failure and
lower all-cause mortality over 24 months of follow-up as compared with medical therapy alone. However, the MITRA-FR
trial [13] was a randomized, open-label controlled trial of
transcatheter edge-to-edge mitral repair MitraClip versus
guideline-directed medical therapy in patients with secondary
MR and heart failure (HF) and showed that MitraClip in addition to guideline-directed medical therapy did not impact
survival or HF hospitalization in patients with secondary MR.

MITRA-FR vs COAPT: Reconciling
the Difference
While MITRA-FR and COAPT trial had conflicting results,
some of the discrepancies in these results can be explained by
baseline characteristics of included patients. Compared with
COAPT, MITRA-FR included patients with more dilated left
ventricles (indexed LV end-diastolic volume of 135 ml/m2 vs
101 ml/m2) and less MR (mean EROA of 0.31 cm2 vs
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0.41 cm2). Moreover, 83% of the patients in MITRA-FR
achieved ≤ 2+ MR after treatment compared with 95% of
the patients in COAPT. Finally, MITRA-FR allowed adjustment of medications by the investigators, whereas COAPT
mandated highest doses of guideline-directed medical therapy
and cardiac resynchronization therapy (CRT) when applicable, with the involvement of HF specialists in the trial adjudication committee and at the enrolling centers.
To reconcile these conflicting data, Grayburn et al. [14]
proposed the concept of proportionate and disproportionate
functional MR, i.e., severity of functional MR relative to the
degree of LV dilation. It is now thought that MitraClip therapy
can be beneficial in patients who have MR disproportionately
higher than what is explained by the degree of LV dilation.
The average patient in MITRA-FR was in the proportionate
MR category but the average patient in COAPT was in the
disproportionate category. Taken all together, the evidence
supports the use of transcatheter edge-to-edge repair in carefully selected patients.

Indications of Transcatheter Edge-to-Edge
Mitral Valve Repair
The US Food and Drug Administration approved MitraClip
on October 25, 2013, for treatment of patients with primary
MR at prohibitive surgical risk. According to the 2014 ACC/
AHA valvular heart disease guidelines and on the 2017 ACC/
AHA valvular heart disease focused update guidelines, transcatheter mitral valve repair may be considered for severely
symptomatic patients (NYHA classes III and IV) with chronic
severe primary MR (stage D) who have favorable anatomy for
the procedure and a reasonable life expectancy but who are at
prohibitive surgical risk because of severe comorbidities and
remain severely symptomatic despite optimal medical therapy
for heart failure (HF) (class IIb, level of evidence: B).
Moreover, the guidelines mention that transcatheter mitral
valve repair provides a less invasive alternative to surgery
for functional MR but is not approved for clinical use or this
indication in the US.
However, based on newer published data as discussed
above, on March 14, 2019, the US Food and Drug
Administration approved MitraClip for treatment of moderate
to severe or severe secondary MR despite optimal guidelinedirected medical therapy. No updated guidelines have
reflected this change as of yet.

Technical Success of the Procedure
Data from randomized controlled trials reported high success
and low complication rates. In the MITRA-FR trial, technical
success at the time of procedure was achieved in 95.8% of

Curr Cardiol Rep (2020) 22: 135

Page 3 of 6 135

patients, and 14.6% of patients experienced procedural complications. At discharge, 91.9% of patients had ≤ 2+ MR. In
COAPT, MitraClip was implanted in 98% of patients in
whom it was attempted, with an average of 1.7 clips.
Device-related complications at 12 months were noted in
3.4% patients. At 30 days, 72.2% of patients had ≤ 1+ MR,
and 93.8% had ≤ 2+ MR. Real-world data from the STS/ACC
TVT registry [15] reported similarly high success and low
complication rates (with 86% of patients having degenerative
or primary MR). Procedure success was reported to be at
91.8%, the mortality at 30 days and at 1 year was 5.2% and
25.8%, respectively, and repeat hospitalization for heart failure at 1 year occurred in 20.2% of patients. Single-leaflet
device attachment occurred in only 1.5%. For postprocedural MR, the rates of grade ≤ 1, grade ≤ 2, and grade
≤ 3 were 61.8%, 31.2%, and 7.0%, respectively. Overall, reduction to moderate or less MR in the absence of cardiac
surgery or in-hospital mortality occurred in 91.8% of patients,
and 1+ or less residual MR is associated with lower heart
failure hospitalization and mortality at 1 year. The vast majority (85.9%) of treated patients were discharged to home.
Moreover, recent data from the STS/ACC TVT registry
[16•, 17•] showed that increasing institutional and operator
experience with transcatheter mitral valve repair with
MitraClip was associated with improvements in procedural
success, procedure time, and procedural complications.

Devices for Edge-to-Edge Mitral Valve Repair
In recent years, the device industry has seen an explosion of
technologies to treat mitral valve disease. In the space of edgeto-edge mitral valve repair, there are currently two systems in
the market. The only transcatheter leaflet repair system with
both FDA and CE mark approval is the MitraClip. MitraClip
has taken center stage in the treatment of mitral regurgitation
since it is supported by multiple clinical trials and has been
Table 1

used in more than 100,000 patients worldwide. The first
MitraClip procedure was performed in 2003, with CE mark
obtained in 2008 and FDA approval for the treatment of primary MR in 2013 and secondary MR in 2019. The MitraClip
system is introduced via femoral transvenous access and transseptal puncture to enter the left atrium/ventricle and consists
of a steerable clip delivery catheter that enables orientation of
the clip device with assistance of 3D real-time transesophageal echo imaging and allows edge-to-edge repair of the
regurgitant mitral valve (Fig. 1). There are four generations
of the MitraClip device with third-generation devices being
the most widely used now (NTR, XTR). The third-generation
MitraClip devices (NTR and XTR clips) require a leaflet
length of at least 6 and 9 mm, respectively, as well as a mitral
valve area (MVA) of ideally > 4 cm2 (Fig. 2 and Table 1). The
MitraClip XTR has a 5-mm-longer clip grasping width due to
longer arms (22 vs. 17 mm (at 120°) compared with the NTR).
Ultimately, the XTR may enable easier and quicker leaflet
grasping, reduce the number of clips required, and expand
transcatheter treatment to patients with less favorable anatomy, such as larger flail gaps. The fourth-generation devices
from the MitraClip family (MitraClip G4) have been approved
for the treatment of mitral regurgitation on July 15, 2019, by
the FDA. The G4 includes four devices (NT, XT, NTW, and
XTW). The G4 MitraClip system allows for independent leaflet grasping, has improvements in clip delivery, and has the
ability for continuous left atrial pressure measurement through
the guiding catheter. The G4 system has four devices (NT,
XT, NTW, and XTW). The NTW has similar longitudinal
but wider dimensions than the NTR (6 mm vs 4 mm) which
results in 50% more coaptation width. One can select the G4
system for wider MR jets and the old system for MV with
small MVAs or restricted and short leaflets [18••] (Table 1 and
Fig. 3).
The PASCAL system (Edwards Life sciences, Irvine, CA)
is a second transcatheter edge-to-edge mitral valve repair system which recently obtained CE mark in February 2019, and

MitraClip device* specification and comparison between different types of clips

Parameter

NT/R

NTW

XT/R

XTW

Grasping width at 120° (mm)
Clip arm length
Clip arm width
Minimum length with all frictional elements engaged
Number of frictional elements on grippers
Leaflet length needed
Ideal baseline MVA

17 mm
9 mm
4 mm
6 mm
4
6 mm
> 4 cm2

17 mm
9 mm
6 mm
6 mm
4
6 mm
> 4 cm2

22 mm
12 mm
4 mm
9 mm
6
9 mm
> 4 cm2

22 mm
12 mm
6 mm
9 mm
6
9 mm
> 4 cm2

Special features

Wider clip arms, independent
leaflet capture

Wider clip arms, independent
leaflet capture

*PASCAL device information is not publically available for now. Special features of the PASCAL device include 10-mm central spacer, ability for
device elongation, and independent grasping of the leaflets
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Fig. 1 The MitraClip system. a
Being delivered through transseptal puncture. b Clip being
oriented to the regurgitant jet. c
Grasping of the leaflets. d View
of the deployed clip in diastole

the pivotal CLASP IID (for degenerative MR) and IIF (for
functional MR) trials are currently underway in the US,
aiming for FDA approval.
The PASCAL system has some unique device features.
The device is designed to be easy to navigate in the left atrium
and left ventricle and offers a high degree of steerability. A 10mm central spacer in the center of the device is intended to
reduce the tension on the grasped valve leaflets. The paddles
of the device are also wider and curved to further reduce
tension. Finally, the system allows for independent grasping
of the valve leaflets.

Fig. 2 Anatomical considerations
for the use of NTR and XTR
MitraClip devices

General and Anatomical Limitations
Evaluation for transcatheter edge-to-edge mitral valve repair requires extensive examination of the mitral valve and its anatomy.
Favorable considerations for this therapy include the central (A2P2) location of the mitral regurgitation with a prolapse width of
< 15 mm and a flail gap of < 10 mm. Moreover, a baseline mitral
valve orifice area of > 4 cm2 is favorable since the application of
the edge-to-edge repair system impacts the opening of the mitral
valve leaflets resulting in a decrease in effective mitral valve
orifice area and could worsen existing mitral stenosis.
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Fig. 3 Dimensions of the
MitraClip system. a Grasping
width at 120° for NT clip. b Arm
width of the NT/XT devices. c
Arm width of the NTW/XTW
devices

Furthermore, a mobile length of the posterior leaflet of > 6 mm
for NT/R and 9 mm for XT/R is desired to allow the arms of the
repair system to sufficiently grasp leaflet tissue in a stable fashion
(Fig. 2 and Table 1). Cleft mitral valves with regurgitation arising
from the cleft, leaflet calcification at the grasping zones, or leaflet
perforations are generally viewed to be unfavorable features for
edge-to-edge repair. None of these anatomical criteria, however,
is viewed to be an absolute contraindication on their own, but
rather, it is viewed as a continuum and operators should practice
caution when selecting patients for this treatment.
Other limitations to these repair systems include a greater
learning curve for operators as shown by a landmark analysis
from the STS/ACC TVT registry showing that procedural
outcomes were evidently better after about 50 cases of
MitraClip, with continued improvements observed up to 200
cases [16•]. Other limitations include that these repair systems
typically do not completely eliminate mitral regurgitation in
all patients but rather result in reduction of MR to the mild to
moderate range, which may be sufficient to achieve a good
clinical outcome.

Other Transcatheter Mitral Valve Therapies
A wide selection of new devices has become available for
treatment of patients with mitral regurgitation that might not
be suitable for edge-to-edge mitral valve repair or as an adjunctive therapy for patients who are suitable. The medical
device industry has seen explosive growth in the transcatheter
and minimally invasive mitral valve repair/replacement device
markets, with multitudes of startups and several innovative
and exciting technologies making it to first-in-human testing
and CE mark approval. Although the only FDA-approved
transcatheter mitral valve repair system is the MitraClip device, several mitral valve repair systems have received CE
mark approval in Europe and are currently in commercial
and registry use. Devices include indirect annuloplasty, direct
annuloplasty, chordal replacement, and transcatheter MV replacement devices. Future studies will define the roles of these
devices in clinical practice.

Conclusions
Mitral regurgitation remains a significant health burden, and
many patients are not suitable for surgical repair or replacement.
Transcatheter edge-to-edge repair with MitraClip is supported
by robust randomized clinical trial data and is the most widely
used transcatheter device for treatment of mitral regurgitation.
A heart team approach should be considered when treating such
patients and efforts should be made to individualize therapy and
understand the general and the anatomical limitations of this
therapy and to select the best device and treatment option for
each patient. Many other transcatheter mitral valve therapies are
being developed and in investigational phases of research.
More research is needed to understand how to best select which
device, which patients to treat, and how to optimize outcomes.
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